本报讯(记者王镜茹)11月26日下午，中国香港新界大埔屋邨宏福苑多栋住宅楼发生火灾，造成重大人员 伤亡。 灾情发生后，广州白云山医药集团股份有限公司(以下简称"白云山")第一时间紧急响应，迅速调配资 源，携旗下广州王老吉大健康产业有限公司捐赠价值500万港元的现金及物资，紧急驰援灾后救助，以 实际行动助力香港受灾同胞渡过难关，为灾后援助贡献力量。 广药白云山，爱心满人间。白云山将密切关注灾情后续进展，与香港同胞同根同心，协力共渡难关。 ...

Group 1 - The core project of Guanghua Pharmaceutical, "Children's Xiao Chai Hu Granules for treating pediatric gastrointestinal colds," has officially launched its Phase II clinical research in Tianjin, marking a significant step in traditional Chinese medicine for this indication [1] - This study is the first to apply the classic formula Xiao Chai Hu Decoction systematically for treating pediatric gastrointestinal colds, utilizing a randomized, double-blind, parallel-controlled modern evidence-based medical approach to explore the efficacy and safety of the treatment [1] - Currently, there are no similar products for children's Xiao Chai Hu Granules available in the market, indicating a potential gap in the market for pediatric proprietary Chinese medicine in this disease area [1] Group 2 - Guanghua Pharmaceutical has established multiple innovation platforms, including a doctoral workstation in Guangdong Province and a provincial enterprise technology center, and has applied for 22 core invention patents for its flagship product, Baiyunshan Xiao Chai Hu Granules [2] - The fingerprint detection method for Xiao Chai Hu Granules has been included in the 2025 edition of the Chinese Pharmacopoeia, showcasing the company's commitment to quality and innovation [2] - In response to a recent fire incident in Hong Kong, the company promptly mobilized resources and donated cash and materials worth 5 million HKD to support disaster relief efforts [2]

Core Viewpoint - Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. announced the inclusion of its subsidiary Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd.'s land and fixed assets into the land reserve plan, with a total compensation amount of approximately 375.24 million yuan and an additional land transfer reward of about 73.32 million yuan, totaling approximately 448.57 million yuan [1][2]. Group 1 - The land and fixed assets of Guanghua Pharmaceutical located at No. 355, Shatai North Road, Baiyun District, Guangzhou, have been included in the land reserve plan [1][2]. - The compensation agreement was signed on November 27, 2025, with the Baiyun District People's Government, and the total compensation amount is 375,244,134 yuan [1][2]. - The compensation includes approximately 366,618,840 yuan for land included in the "Three Olds" renovation program and 8,625,294 yuan for land not included in this program [2]. Group 2 - The total compensation and land transfer reward amount to approximately 448,567,902 yuan, contingent upon meeting the "net land" standards [1][2]. - The transaction does not constitute a related party transaction or a major asset restructuring as defined by relevant regulations [1][3]. - The transaction was approved by the company's Strategic Development and Investment Committee, and does not require further approval from the board or shareholders [3]. Group 3 - The land area involved in the transaction is 29,429.56 square meters, with a total building area of 10,530.35 square meters, including offices, workshops, and warehouses [6]. - The land has a clear ownership status, with no existing mortgages or legal restrictions [7]. - The land was acquired in 2002 with a usage period of 50 years, and has been depreciated for 23 years [8]. Group 4 - The compensation pricing is based on evaluations from two real estate appraisal firms, with the average land price used to determine the compensation amount [9][10]. - The compensation for the "Three Olds" portion is calculated at 50% of the market assessed land price, resulting in approximately 366,618,840 yuan [9]. - The non-"Three Olds" portion is evaluated at approximately 8,625,294 yuan based on different appraisal methods [10]. Group 5 - The agreement stipulates that the first compensation payment of 80 million yuan will be made after the land ownership is deregistered, with subsequent payments contingent on land transfer completion [13]. - The company plans to manage logistics through warehouse leasing during the transition period, ensuring no personnel displacement [15]. - The land reserve will not lead to related party transactions or competition within the industry [15].

Group 1 - Baidu's Biotech Company, Bai'ao Saitou, is set to launch its IPO on the Sci-Tech Innovation Board, aiming to raise 1.185 billion yuan for early drug development services, antibody drug research, and working capital [1] - Changchun High-tech's subsidiary received approval for its clinical trial application for GenSci142 capsules, marking the first approval under the new 30-day review channel for innovative drugs [2] - Antu Bio announced it received 18 medical device registration certificates, enhancing its product offerings and competitiveness in the market [3] Group 2 - Yidu Tech reported a revenue of 358 million yuan for the six months ending September 30, 2025, reflecting an 8.7% year-on-year growth, with a narrowed loss of 15.76 million yuan [4] - Baiyunshan's subsidiary, Guanghua Pharmaceutical, will receive a total compensation of approximately 449 million yuan for land and fixed assets included in a land reserve program, which aligns with the company's long-term development goals [5]

白云山（600332）(00874)发布公告，本公司附属子公司光华制药位于广州市白云区沙太北路355号地块 及固定资产被纳入《白云同和片区土地储备实施方案》拟收储土地范围。于2025年11月27日，光华制药 与同和街道办事处订立土地收储补偿协议。根据该协议，本次地块收储补偿金额为人民币3.75亿元，地 块达到"净地"标准等条件，可获得交地奖励约人民币7332.38万元，上述补偿及交地奖励合计约人民币 4.49亿元。 ...

Core Viewpoint - Baiyunshan (00874) announced that its subsidiary Guanghua Pharmaceutical's land and fixed assets in Guangzhou have been included in the land reserve implementation plan for the Baiyun Tonghe area, with a compensation agreement signed for land storage [1] Summary by Categories Land Acquisition - Guanghua Pharmaceutical's land located at No. 355, Shatai North Road, Baiyun District, Guangzhou, is set to be included in the land reserve plan [1] - A land storage compensation agreement was established with the Tonghe Street Office, effective until November 27, 2025 [1] Financial Implications - The total compensation amount for the land storage is approximately RMB 375 million [1] - The land will meet the "net land" standard, allowing for an additional land transfer reward of about RMB 73.32 million [1] - The combined total of compensation and land transfer reward amounts to approximately RMB 449 million [1]

Core Viewpoint - Baiyunshan (600332.SH) announced that its subsidiary, Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd., has had its land and fixed assets included in the land reserve implementation plan for the Baiyun Tonghe area, indicating a strategic move to enhance its asset base and operational capacity [1] Group 1: Land Acquisition Details - The land in question is located at 355 Shatai North Road, Baiyun District, Guangzhou [1] - A compensation agreement for the state-owned land use rights was signed on November 27, 2025, with the Baiyun District People's Government [1] - The total compensation amount for the land acquisition is approximately 375,244,134 RMB [1] Group 2: Financial Implications - The land will meet the "net land" standard, allowing the company to receive an additional land transfer reward of about 73,323,768 RMB [1] - The total financial benefit from the land acquisition, including both compensation and rewards, amounts to approximately 448,567,902 RMB [1] - The company and Guanghua Pharmaceutical will process the compensation according to relevant accounting standards [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 自願公告 訂立土地收儲補償協議 土地收儲補償協議的主要條款如下： 本公告乃由廣州白雲山醫藥集團股份有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願作 出。 緒言 本公司附屬子公司光華製藥位於廣州市白雲區沙太北路355號地塊及固定資產被納入《白雲同和片區 土地儲備實施方案》擬收儲土地範圍。於2025年11月27日，光華製藥與同和街道辦事處訂立土地收儲 補償協議。根據該協議，本次地塊收儲補償金額為人民幣375,244,134元，地塊達到「淨地」標準等條 件，可獲得交地獎勵約人民幣73,323,768元，上述補償及交地獎勵合計約人民幣448,567,902元。 土地收儲補償協議 訂約方： 1. 廣州市白雲區人民政府同和街道辦事處（甲方） 2. 廣州白雲山光華製藥股份有限公司（乙方） 收儲補償款金額： 人民幣375,244,134元 1 交地獎勵： 達到「淨地」標準交地的，給予乙方交地獎勵人民幣73,3 ...

证券代码：600332 证券简称：白云山 公告编号：2025-081 广州白云山医药集团股份有限公司 关于子公司土地收储补偿的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●广州白云山医药集团股份有限公司（以下简称"本公司""公司"）子公 司广州白云山光华制药股份有限公司（以下简称"光华制药"）位于广州市白云 区沙太北路 355 号地块及固定资产（以下简称"交易标的"）被纳入《白云同和 片区土地储备实施方案》拟收储土地范围。光华制药于 2025 年 11 月 27 日与广 州市白云区人民政府同和街道办事处签订《国有土地使用权收储补偿协议》（以 下简称"本协议""补偿协议"）。本次地块收储补偿金额为 375,244,134 元（人 民币，下同），地块达到"净地"标准等条件，可获得交地奖励约 73,323,768 元，合计约 448,567,902 元。公司及光华制药将按照《企业会计准则》相关规定 对补偿款进行会计处理。 ●本次土地收储事项不构成关联交易，也不构成《上市公司重大资产重组管 理办法》规定的重大 ...

Core Viewpoint - Baiyunshan Pharmaceutical Group's stock performance shows a slight decline, with significant financing activity indicating investor interest despite the drop in share price [1][2]. Financing Activity - On November 26, Baiyunshan's stock fell by 0.42%, with a trading volume of 257 million yuan. The financing buy-in amounted to 28.26 million yuan, while financing repayment was 17.54 million yuan, resulting in a net financing buy of 10.73 million yuan [1]. - As of November 26, the total financing and securities lending balance for Baiyunshan was 864 million yuan, with the financing balance accounting for 2.37% of the circulating market value, indicating a high level compared to the past year [1]. Company Overview - Baiyunshan, established on September 1, 1997, and listed on February 6, 2001, is based in Guangzhou, China. The company specializes in the research, development, manufacturing, and sales of traditional Chinese and Western medicines, chemical raw materials, and health products [2]. - The revenue composition for Baiyunshan includes 69.32% from large commercial operations, 16.79% from health products, and 12.53% from traditional Chinese medicine [2]. Financial Performance - For the period from January to September 2025, Baiyunshan reported a revenue of 61.606 billion yuan, reflecting a year-on-year growth of 4.31%. The net profit attributable to shareholders was 3.31 billion yuan, with a growth of 4.78% [2]. Dividend Distribution - Since its A-share listing, Baiyunshan has distributed a total of 10.906 billion yuan in dividends, with 4.359 billion yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, the top ten circulating shareholders of Baiyunshan include China Securities Finance Corporation, holding 47.278 million shares, and Hong Kong Central Clearing Limited, which reduced its holdings by 20.437 million shares [3].